CA2612282C - Use of a cytokine from the interleukin-6 family in the preparation of a composition for combined administration with interferon-alpha - Google Patents
Use of a cytokine from the interleukin-6 family in the preparation of a composition for combined administration with interferon-alpha Download PDFInfo
- Publication number
- CA2612282C CA2612282C CA2612282A CA2612282A CA2612282C CA 2612282 C CA2612282 C CA 2612282C CA 2612282 A CA2612282 A CA 2612282A CA 2612282 A CA2612282 A CA 2612282A CA 2612282 C CA2612282 C CA 2612282C
- Authority
- CA
- Canada
- Prior art keywords
- ifn
- alpha
- cytokine
- family
- pegylated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000004127 Cytokines Human genes 0.000 title claims abstract description 102
- 108090000695 Cytokines Proteins 0.000 title claims abstract description 102
- 108090001005 Interleukin-6 Proteins 0.000 title claims abstract description 83
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 102000004889 Interleukin-6 Human genes 0.000 title description 71
- 239000000203 mixture Substances 0.000 title description 8
- 108010047761 Interferon-alpha Proteins 0.000 title description 4
- 102000006992 Interferon-alpha Human genes 0.000 title description 4
- 229940100601 interleukin-6 Drugs 0.000 title description 2
- 102100028892 Cardiotrophin-1 Human genes 0.000 claims abstract description 83
- 108010041776 cardiotrophin 1 Proteins 0.000 claims abstract description 83
- 108090000630 Oncostatin M Proteins 0.000 claims abstract description 52
- 102000004140 Oncostatin M Human genes 0.000 claims abstract description 52
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 24
- 201000010099 disease Diseases 0.000 claims abstract description 23
- 230000003612 virological effect Effects 0.000 claims abstract description 22
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 108010050904 Interferons Proteins 0.000 claims description 27
- 102000014150 Interferons Human genes 0.000 claims description 27
- 229940079322 interferon Drugs 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 22
- 241000710188 Encephalomyocarditis virus Species 0.000 claims description 15
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 241000700605 Viruses Species 0.000 claims description 11
- 208000005176 Hepatitis C Diseases 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 230000001766 physiological effect Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000036961 partial effect Effects 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 28
- 238000000034 method Methods 0.000 abstract description 13
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 abstract description 8
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 abstract description 8
- 108010002871 cardiotrophin-like cytokine Proteins 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 208000032839 leukemia Diseases 0.000 abstract description 6
- 241000711549 Hepacivirus C Species 0.000 description 70
- 210000004027 cell Anatomy 0.000 description 67
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 35
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 35
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 33
- 102000006381 STAT1 Transcription Factor Human genes 0.000 description 33
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 33
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 33
- 230000000840 anti-viral effect Effects 0.000 description 30
- 230000004913 activation Effects 0.000 description 19
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 230000003993 interaction Effects 0.000 description 13
- 230000010076 replication Effects 0.000 description 13
- 208000036142 Viral infection Diseases 0.000 description 11
- 230000009385 viral infection Effects 0.000 description 11
- 230000026731 phosphorylation Effects 0.000 description 10
- 238000006366 phosphorylation reaction Methods 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 238000002648 combination therapy Methods 0.000 description 8
- 230000000120 cytopathologic effect Effects 0.000 description 7
- 230000019491 signal transduction Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 238000011529 RT qPCR Methods 0.000 description 6
- 208000002672 hepatitis B Diseases 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000015696 Interleukins Human genes 0.000 description 5
- 108010063738 Interleukins Proteins 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000002459 sustained effect Effects 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 4
- 101000852865 Homo sapiens Interferon alpha/beta receptor 2 Proteins 0.000 description 4
- 102100036718 Interferon alpha/beta receptor 2 Human genes 0.000 description 4
- -1 STAT2 Proteins 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 3
- 102000016911 Deoxyribonucleases Human genes 0.000 description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 3
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 3
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 229960000329 ribavirin Drugs 0.000 description 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 206010059313 Anogenital warts Diseases 0.000 description 2
- 201000006082 Chickenpox Diseases 0.000 description 2
- 208000006154 Chronic hepatitis C Diseases 0.000 description 2
- 208000000907 Condylomata Acuminata Diseases 0.000 description 2
- 206010019715 Hepatic viral infections Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 102000014746 Interferon-Stimulated Gene Factor 3 Human genes 0.000 description 2
- 108010064052 Interferon-Stimulated Gene Factor 3 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 2
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 2
- 102000001712 STAT5 Transcription Factor Human genes 0.000 description 2
- 206010046980 Varicella Diseases 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 2
- 201000004201 anogenital venereal wart Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000010710 hepatitis C virus infection Diseases 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 201000006747 infectious mononucleosis Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 108010092851 peginterferon alfa-2b Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 108030002617 2'-5' oligoadenylate synthases Proteins 0.000 description 1
- YYYARFHFWYKNLF-UHFFFAOYSA-N 4-[(2,4-dimethylphenyl)diazenyl]-3-hydroxynaphthalene-2,7-disulfonic acid Chemical compound CC1=CC(C)=CC=C1N=NC1=C(O)C(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=C12 YYYARFHFWYKNLF-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 description 1
- 101150009057 JAK2 gene Proteins 0.000 description 1
- 108010000837 Janus Kinase 1 Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 101800001169 Protein p48 Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 102000004265 STAT2 Transcription Factor Human genes 0.000 description 1
- 108010081691 STAT2 Transcription Factor Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 102000015774 TYK2 Kinase Human genes 0.000 description 1
- 108010010057 TYK2 Kinase Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010217 densitometric analysis Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 102000016557 gamma Subunit Interferon-Stimulated Gene Factor 3 Human genes 0.000 description 1
- 108010067667 gamma Subunit Interferon-Stimulated Gene Factor 3 Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 229960003507 interferon alfa-2b Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 238000001821 nucleic acid purification Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940002988 pegasys Drugs 0.000 description 1
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 1
- 229960003931 peginterferon alfa-2b Drugs 0.000 description 1
- 229940106366 pegintron Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000012755 real-time RT-PCR analysis Methods 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2073—IL-11
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5415—Leukaemia inhibitory factor [LIF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5431—IL-11
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ESP200501468 | 2005-06-16 | ||
| ES200501468A ES2302402B1 (es) | 2005-06-16 | 2005-06-16 | Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa. |
| PCT/ES2006/000353 WO2006134195A2 (es) | 2005-06-16 | 2006-06-16 | Uso de una citoquina de la familia de interleuquina-6 en la preparación de una composición para administración combinada con interperón-alfa |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2612282A1 CA2612282A1 (en) | 2006-12-21 |
| CA2612282C true CA2612282C (en) | 2014-03-25 |
Family
ID=37532659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2612282A Expired - Fee Related CA2612282C (en) | 2005-06-16 | 2006-06-16 | Use of a cytokine from the interleukin-6 family in the preparation of a composition for combined administration with interferon-alpha |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7829077B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP1905447A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP5154412B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN101257918B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2006258966B8 (cg-RX-API-DMAC10.html) |
| BR (1) | BRPI0611988A2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2612282C (cg-RX-API-DMAC10.html) |
| ES (1) | ES2302402B1 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2007016060A (cg-RX-API-DMAC10.html) |
| RU (1) | RU2413529C2 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2006134195A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA106591C2 (uk) * | 2008-07-23 | 2014-09-25 | Тамара Алєксандровна Віткалова | Спосіб лікування гепатиту с з використанням інтерферону та інтерлейкіну-1 |
| JP2010059081A (ja) * | 2008-09-02 | 2010-03-18 | Okayama Univ | オンコスタチンｍを含有する抗ｈｃｖ剤およびその利用 |
| ES2342529B1 (es) * | 2008-10-07 | 2011-05-11 | Proyecto De Biomedicina Cima, S.L. | Oncostatina m como potenciador de la actividad inmunoestimuladora de celulas epiteliales humanas. |
| WO2011098644A2 (es) | 2010-02-09 | 2011-08-18 | Proyecto De Biomedicina Cima, S.L. | Composiciones para el tratamiento de enfermedades infecciosas y tumorales |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| CN121974842A (zh) | 2016-05-10 | 2026-05-05 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| CN110636854A (zh) | 2017-03-31 | 2019-12-31 | 阿卡尼斯生物技术F&E有限责任两合公司 | 非黑素瘤皮肤癌(nmsc)的预防和治疗 |
| EP4717317A3 (en) | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| CN113197910B (zh) * | 2021-05-14 | 2022-09-23 | 苏州大学 | 一种基于阿司匹林及其代谢产物提高干扰素抗病毒活性的抗病毒药盒 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6348191B1 (en) * | 1986-07-08 | 2002-02-19 | Genetics Institute, Inc. | Production and use of IL-6 |
| IE67035B1 (en) * | 1986-07-08 | 1996-02-21 | Genetics Inst | Production and use of non-glycosylated IL-6 |
| US6284237B1 (en) * | 1986-07-08 | 2001-09-04 | Steven C. Clark | Methods of treatment using IL-6 |
| US5372808A (en) * | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
| US5766582A (en) | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
| TW426523B (en) | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
| ES2214551T3 (es) * | 1995-11-02 | 2004-09-16 | Schering Corporation | Terapia de infusion continua de citocinas a baja dosis. |
| US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| GB9609932D0 (en) * | 1996-05-13 | 1996-07-17 | Hoffmann La Roche | Use of IL-12 and IFN alpha for the treatment of infectious diseases |
| EP2298900A1 (en) * | 1996-09-17 | 2011-03-23 | Novartis Vaccines and Diagnostics, Inc. | Compositions and methods for treating intracellular diseases |
| TW589189B (en) * | 1997-08-04 | 2004-06-01 | Scras | Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis |
| JP2002532556A (ja) * | 1998-12-22 | 2002-10-02 | シェリング・コーポレーション | Ｃ型肝炎ウイルス感染のインターロイキン−１０での処置 |
| ES2200646B1 (es) * | 2001-09-21 | 2005-05-01 | Fundacion Para La Investigacion Medica Aplicada | Uso de la cardiotrofina en enfermedades hepaticas. |
| TW200408407A (en) * | 2001-11-30 | 2004-06-01 | Dana Farber Cancer Inst Inc | Methods and compositions for modulating the immune system and uses thereof |
| RU2222345C2 (ru) * | 2002-01-21 | 2004-01-27 | Волчек Игорь Анатольевич | Фармацевтическая композиция цитокинового и иммуномодулирующего действия |
| US20050027110A1 (en) * | 2003-07-24 | 2005-02-03 | Michael Russell | Drug delivery in the nervous system |
-
2005
- 2005-06-16 ES ES200501468A patent/ES2302402B1/es not_active Expired - Fee Related
-
2006
- 2006-06-16 MX MX2007016060A patent/MX2007016060A/es active IP Right Grant
- 2006-06-16 WO PCT/ES2006/000353 patent/WO2006134195A2/es not_active Ceased
- 2006-06-16 RU RU2008100307/15A patent/RU2413529C2/ru not_active IP Right Cessation
- 2006-06-16 AU AU2006258966A patent/AU2006258966B8/en not_active Ceased
- 2006-06-16 CA CA2612282A patent/CA2612282C/en not_active Expired - Fee Related
- 2006-06-16 CN CN2006800299002A patent/CN101257918B/zh not_active Expired - Fee Related
- 2006-06-16 EP EP06794028A patent/EP1905447A4/en not_active Withdrawn
- 2006-06-16 BR BRPI0611988-3A patent/BRPI0611988A2/pt not_active IP Right Cessation
- 2006-06-16 JP JP2008516350A patent/JP5154412B2/ja not_active Expired - Fee Related
- 2006-06-16 US US11/922,221 patent/US7829077B2/en not_active Expired - Fee Related
-
2010
- 2010-09-22 US US12/887,843 patent/US20110027224A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2008100307A (ru) | 2009-07-27 |
| US20090130055A1 (en) | 2009-05-21 |
| CA2612282A1 (en) | 2006-12-21 |
| JP5154412B2 (ja) | 2013-02-27 |
| WO2006134195A8 (es) | 2008-01-31 |
| BRPI0611988A2 (pt) | 2010-10-13 |
| CN101257918B (zh) | 2011-09-21 |
| RU2413529C2 (ru) | 2011-03-10 |
| WO2006134195A2 (es) | 2006-12-21 |
| EP1905447A4 (en) | 2012-04-25 |
| AU2006258966B2 (en) | 2011-11-17 |
| EP1905447A2 (en) | 2008-04-02 |
| ES2302402A1 (es) | 2008-07-01 |
| MX2007016060A (es) | 2008-03-10 |
| CN101257918A (zh) | 2008-09-03 |
| AU2006258966B8 (en) | 2011-12-08 |
| US7829077B2 (en) | 2010-11-09 |
| AU2006258966A1 (en) | 2006-12-21 |
| JP2008546672A (ja) | 2008-12-25 |
| WO2006134195A3 (es) | 2007-04-19 |
| US20110027224A1 (en) | 2011-02-03 |
| ES2302402B1 (es) | 2009-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20110027224A1 (en) | Use of a cytokine from the interleukin-6 family in the preparation of a composition for combined administration with interferon-alpha | |
| Schreiber | The role of type I interferons in the pathogenesis and treatment of COVID-19 | |
| Chen et al. | Functional comparison of interferon‐α subtypes reveals potent hepatitis B virus suppression by a concerted action of interferon‐α and interferon‐γ signaling | |
| Frese et al. | Interferon-γ inhibits replication of subgenomic and genomic hepatitis C virus RNAs | |
| Sato et al. | Antiviral response by natural killer cells through TRAIL gene induction by IFN–α/β | |
| KR101755058B1 (ko) | 특정 ｈｃｖ ｎｓ５ａ 억제제 및 ｈｃｖ ｎｓ３ 프로테아제 억제제의 조합물 | |
| Zhu et al. | Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication | |
| Nair et al. | Interferon regulatory factor-1 protects from fatal neurotropic infection with vesicular stomatitis virus by specific inhibition of viral replication in neurons | |
| Castelruiz et al. | Interferon alfa subtypes and levels of type I interferons in the liver and peripheral mononuclear cells in patients with chronic hepatitis C and controls | |
| WO2017171631A1 (en) | Non-activated t cells expressing exogenous virus-specific t cell receptor (tcr) | |
| JP2008524160A (ja) | インターフェロンβによるアジア人種におけるＣ型肝炎の治療 | |
| Martínez-Espinoza et al. | Current landscape of IFN-λ: induction, inhibition, and potential clinical applications to treat respiratory viral infections | |
| Gruber et al. | Differential signaling of cmvIL‐10 through common variants of the IL‐10 receptor 1 | |
| CN114246937B (zh) | 白细胞介素37与干扰素联用在治疗病毒感染中的应用 | |
| US20090074721A1 (en) | Methods for treating viral infection with oral or injectibel drug solution | |
| EP2535057A2 (en) | Compositions for the treatment of infectious and tumoural diseases | |
| WO2005016226A2 (en) | Pharmaceutical compositions comprising ccr5 antagonists | |
| Elemam et al. | CXCL10 chemokine: a critical player in RNA and DNA viral infections. Viruses. 2022; 14: 2445 | |
| CN114404572A (zh) | 一种抗SARS-CoV2病毒感染导致的细胞因子风暴的药物 | |
| Lin et al. | [12] TELAPREVIR (VX-950) IS A POTENT INHIBITOR OF HCV NS3 PROTEASES DERIVED FROM GENOTYPE NON-1 HCV-INFECTED PATIENTS | |
| Chen et al. | IFNA2 p. Ala120Thr impairs the inhibitory activity of Interferon-α2 against the hepatitis B virus through altering its binding to the receptor | |
| Masihi | Novel concepts for anti-infective activity of cytokines, chemokines and diverse agents | |
| Masihi | Progress on novel immunomodulatory agents for HIV-1 infection and other infectious diseases | |
| Huang et al. | [13] IN VITRO EVALUATION OF COMBINATION TREATMENT OF ACH-806 WITH INTERFERON; VX-950 AND NM 107 | |
| Nair et al. | Interferon Regulatory Factor-1 Protects from Fatal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20160616 |